Structure · schematic
Peptide chain of 7 amino acids · Neuropeptid
Schematic representation of the amino acid chain — not a chemical structural formula. Each node represents one amino acid.
Research areas*
* Contexts in which the peptide has been scientifically studied — not assured or recommended effects.
Mechanism of action
- PE-22-28 is a shortened analog of spadin, an endogenous peptide derived from the propeptide of the sortilin/neurotensin receptor 3.
- It inhibits the potassium channel TREK-1, which is involved in mood regulation and depression.
- In preclinical models a rapid antidepressant effect and promotion of neurogenesis and synaptogenesis are described.
- PE-22-28 was developed as a more stable, more bioavailable spadin derivative.
Research status
- PE-22-28 and the parent peptide spadin have so far been studied exclusively preclinically.
- Basic research describes spadin as a TREK-1 inhibitor with antidepressant potential; shortened analogs such as PE-22-28 showed better stability and effect in rodent models.
- Controlled human studies do not exist.
- Safety and efficacy in humans are not demonstrated.
Evidence level
Cited studies
Known risks
- 01No human studies — safety profile entirely unknown
- 02Interference with TREK-1/mood signalling with unclear consequences
- 03Interactions with antidepressants not characterised
- 04Product quality cannot be verified from unapproved sources
Frequently asked questions
What is PE-22-28?
PE-22-28 is a shortened analog of spadin, an endogenous peptide derived from the propeptide of the sortilin/neurotensin receptor 3.
What type of peptide is PE-22-28?
PE-22-28 belongs to the Neuropeptide class.
Is PE-22-28 legal in Germany?
PE-22-28 is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.
Where can I buy PE-22-28?
Peptica sells nothing and names no sources. PE-22-28 is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.
Is PE-22-28 banned in sport (WADA)?
PE-22-28 is currently not on the WADA Prohibited List.
What are the known risks of PE-22-28?
Documented risks include: No human studies — safety profile entirely unknown; Interference with TREK-1/mood signalling with unclear consequences. This is not a complete safety assessment and not medical advice — see the risks section for the full list.
How well researched is PE-22-28?
The evidence is classified as “preclinical”. 2 studies are cited on this page.
Which peptides are related to PE-22-28?
Closely related entries: Semax, Selank. A direct side-by-side comparison is available via the compare function.
Related entries
Legal status
Germany
not approvedAustria
not approvedSwitzerland
not approvedEU
not approvedUSA
not approvedCanada
not approvedLegal status varies by country and can change. This is not legal advice.
Sources & methodology
- 2 peer-reviewed studies cited, linked to PubMed where available.
- Molecular data verified against PubChem and primary literature.
- Editorial standard: no dosage guidance, no sources, evidence level stated explicitly.
Last editorially reviewed: 30 May 2026
Legal assessment
PE-22-28 is not approved as a medicine and is solely a preclinical research substance. Not on the WADA Prohibited List. Obtaining it as a research chemical carries considerable quality and safety risks.
Important notice
This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans.
This site does not sell any substances and names no sources for unapproved substances. For medical questions, please consult qualified medical professionals.
Anzeige
Reserviert für sorgfältig ausgewählte Partner — Telemedizin, Diagnostik, legale topische Anwendungen.